Updated daily
Drug recalls
Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.
Class IITerminatedSep 23, 2015Hydromorphone 50 mg/ml + Fentanyl 3Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1675-2015Class IITerminatedSep 23, 2015Hydromorphone 45 mg/ml + Fentanyl 10Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1674-2015Class IITerminatedSep 23, 2015Hydromorphone 35 mg/ml + Bupivacaine 4 mg/ml Intrathecal SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1673-2015Class IITerminatedSep 23, 2015Hydromorphone 35 mg/ml + Bupivacaine 10 mg/ml + Baclofen 1Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1672-2015Class IITerminatedSep 23, 2015Hydromorphone 3 mg/ml + Baclofen 2Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1671-2015Class IITerminatedSep 23, 2015Hydromorphone 20 mg/ml + Clonidine 1Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1670-2015Class IITerminatedSep 23, 2015Hydromophone 10 mg/ml + Clonidine 300 mcg/ml + Baclofen 120 mcg/ml Intrathecal SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1669-2015Class IITerminatedSep 23, 2015Calmme InjectableLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1668-2015Class IITerminatedSep 23, 2015Buckshot InjectableLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1667-2015Class IITerminatedSep 23, 2015Bi-Mix MediumLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1666-2015Class IITerminatedSep 23, 2015Bi-Mix (20/1) InjectableLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1665-2015Class IITerminatedSep 23, 2015Bi-Mix #1Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1664-2015Class IITerminatedSep 23, 2015Zinc Chloride 25mg/ml InjectableLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1663-2015Class IITerminatedSep 23, 2015Zinc 5 mg/ml InjectableLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1662-2015Class IITerminatedSep 23, 2015Vancomycin 25 mg/ml Ophthalmic SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1661-2015Class IITerminatedSep 23, 2015Testosterone 75 mg and B12 6 mg PelletLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1660-2015Class IITerminatedSep 23, 2015Testosterone 200 mg Anastrazole 9 mg PelletLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1659-2015Class IITerminatedSep 23, 2015Testosterone 200 mg Anastrazole 1 mg PelletLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1658-2015Class IITerminatedSep 23, 2015Testosterone 60 mg Anastrazole 4 mg PelletLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1657-2015Class IITerminatedSep 23, 2015Testosterone 80 mg PelletLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1656-2015Class IITerminatedSep 23, 2015Testosterone 75 mg PelletLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1655-2015Class IITerminatedSep 23, 2015Testosterone 72.5 mg PelletLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1654-2015Class IITerminatedSep 23, 2015Testosterone 70 mg PelletLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1653-2015Class IITerminatedSep 23, 2015Testosterone 62.5 mg PelletLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1652-2015Class IITerminatedSep 23, 2015Testosterone 50 mg PelletLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1651-2015Class IITerminatedSep 23, 2015Testosterone USPLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1650-2015Class IITerminatedSep 23, 2015Testosterone Propionate 100 mg/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1649-2015Class IITerminatedSep 23, 2015Testosterone USP Aqueous 200 mg/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1648-2015Class IITerminatedSep 23, 2015Testosterone Enanthate 200 mg/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1647-2015Class IITerminatedSep 23, 2015Testosterone Cypionate 200 mg/ml Anastrazole 0.25 mg/ml Cholecalciferol 50Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1646-2015Class IITerminatedSep 23, 2015Testosterone Cypionate 200 mg/ml Anastrazole 2 mg/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1645-2015Class IITerminatedSep 23, 2015Testosterone Cypionate 200 mg/ml Anastrazole 0.5 mg/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1644-2015Class IITerminatedSep 23, 2015Testosterone Cypionate 200 mg/ml Anastrazole 0.25 mg/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1643-2015Class IITerminatedSep 23, 2015Testosterone Cypionate 200mg/ml Injection Multi-Dose VialLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1642-2015Class IITerminatedSep 23, 2015Testosterone Cypionate 150 mg/ml Injection Multi-Dose VialLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1641-2015Class IITerminatedSep 23, 2015Testosterone Cypionate 100 mg/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1640-2015Class IITerminatedSep 23, 2015SUPER LIPO InjectableLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1639-2015Class IITerminatedSep 23, 2015Sufentanil 50 mcg/ml + Bupivacaine 0.25 mg/ml SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1638-2015Class IITerminatedSep 23, 2015Sufentanil 50 mcg/ml SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1637-2015Class IITerminatedSep 23, 2015Sufentanil 45 mcg/ml + Bupivacaine 5 mg/ml SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1636-2015